Dr. Beman Khulpateea is a Fellowship-trained gynecologic oncologist, providing advanced surgical options for women facing the challenge of a GYN cancer diagnosis.
Inflammatory bowel disease, or IBD, includes disorders that cause inflammation of the intestines. IBD is treated at Mercy by expert gastroenterologists.
The Minimally Invasive Brain and Spine Center at Mercy is a leading neurosurgical center offering state-of-the-art technologies and clinical expertise to provide advanced treatment options.
Mercy offers emergency care on the Downtown Baltimore campus 24 hours a day, 7 days a week (410-332-9477) with access to a trained emergency medicine team, diagnostic services and consultations with specialists.
In case of an Emergency, Dial 911 and follow the instructions of the EMS (Emergency Medical Services) team.
Mercy Medical Center's downtown campus includes our Main Hospital - The Mary Catherine Bunting Center, McAuley Plaza and The Weinberg Center.
General visiting hours at Mercy are 11:00 am to 8:30 pm. Hours vary by floor, please check with the nursing staff or call 410-332-9555.
Currently Displaying: Active Clinical Trials
This study will evaluate the efficacy and safety of ipatasertib in combination with atezolizumab and paclitaxel in locally advanced or metastatic Triple-Negative Breast Cancer (TNBC) previously untreated in this setting. (ClinicalTrials.gov ID#: NCT04177108)
This is a research study comparing Atezolizumab (Anti-PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple‑negative breast cancer. (Clinicaltrials.gov ID#: NCT03498716)
This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). This study will help to show whether weight loss programs should be a part of breast cancer treatment. (Clinicaltrials.gov ID#: NCT02750826)
This trial compares the efficacy and safety of elacestrant to the standard of care fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on at least one endocrine therapy. (ClinicalTrials.gov ID#: NCT03778931)
This study is designed for patients desiring nipple reconstruction following surgery for breast cancer and breast reconstruction. Eligible patients will receive a surgical procedure to reconstruct one or both nipples utilizing the COOK® Biodesign® Plastic Surgery Matrix. The study is designed to evaluate the benefit of this device in achieving effective and aesthetic nipple reconstruction. Patients will be evaluated at the time of the procedure and at 1 week, 4 weeks, 3 months, 6 months, and 12 months after surgery to examine the projection of their reconstructed nipple(s) and patient satisfaction (Cook Medical Study 09-009; Clinicaltrials.gov ID#: NCT01216319).
The purpose of this registry is to create a large-scale, population-based database. This database will match health information to genome information to look at the Agendia Breast Cancer suite and new gene associations. The Agendia Breast Cancer Suite includes MammaPrint® and BluePrint™, which are tests that help your doctor analyze and profile your breast cancer tumor. DiscoverPrint is for research purposes only. (Clinicaltrials.gov ID#: NCT03053193)
This is an open-label, randomized, multicenter Phase 3 study to compare the efficacy and safety of Sacituzumab Govitecan versus TPC in subjects with metastatic or locally recurrent inoperable HR+/HER2- MBC, after failure of at least 2, and no more than 4, prior chemotherapy regimens for metastatic disease. (Clinicaltrials.gov ID#: NCT03901339)
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (Clinicaltrials.gov ID#: NCT03701334).
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Non Small Cell Lung Cancer, Ovarian Cancer or Breast Cancer. (Clinicaltrials.gov ID#: NCT03937154)
This is a phase III randomized trial evaluate the efficacy and safety of pembrolizumab for women with triple-negative breast cancer who have residual invasive cancer or positive lymph nodes after neoadjuvant chemotherapy. (Clinicaltrials.gov ID#: NCT02954874)
This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) or cannot be removed completely with surgery. (Clinicaltrials.gov ID#: NCT03975647)
This is an observational study for women who are receiving Intraoperative Radiation Therapy (IORT) following breast-conserving surgery. (ClinicalTrials.gov ID#: NCT01570998)
The Hoffberger Breast Center at Mercy Medical Center in Baltimore, Maryland, features some of the Mid-Atlantic’s top rated breast cancer doctors, surgeons and specialists in a comfortable, caring atmosphere within The Weinberg Center for Women’s Health & Medicine. The Breast Center provides the Baltimore region with expertise in patient treatment for diseases and conditions including breast cancer, breast lumps, breast calcifications, nipple discharge and cysts. Our Doctors offer advanced treatment options and were the first in Maryland to treat patients using (IORT) intraoperative radiation therapy.
Dr. Gauri Bedi, Associate Director of The Hoffberger Breast Center, is a leading breast cancer doctor in the Baltimore area regarded by her patients as an accomplished breast surgeon.